Research | Sidney Kimmel Cancer Center
Our 5 NCI-designated Research Programs: Cancer Cell Biology & Signaling, Molecular Biology & Genetics, Prostate Cancer, Breast Cancer, and Gastrointestinal Cancer.
Related Articles
3D-Printed Organ-Realistic Phantoms to Verify Quantitative SPECT/CT Accuracy for 177Lu-PSMA-617 Treatment Planning
Background/Objectives: Accurate patient-specific dosimetry is essential for optimizing radiopharmaceutical therapy (RPT), but current tools lack validation in clinically realistic conditions. This work aimed to develop…
Community Learning and Experience About Research’ Program Connects Community Members with Sidney Kimmel Comprehensive Cancer Center Researchers | Jefferson Health
The program gives individuals a look into the laboratory & provides insight to researchers from our community’s perspective
Focus | Innovative Cancer Care | Elekta
Explore cutting-edge cancer treatment and healthcare innovations in Focus, Elekta’s Online Magazine. Stay informed with the latest articles. Discover more.
66th ASH Annual Meeting: 613. Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Clinical Trials in Pediatric and Young Adult Patients
Lindsay Wilde, MD, Thomas Jefferson University and Joanna S. Yi, MD, Baylor College of Medicine/Texas Children’s
Paper: Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial
Program: Oral and Poster Abstracts Type: Oral Session: 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in…
66th ASH Annual Meeting: Blood Drop: Translational Research Training in Hematology (TRTH) Program
Sara E. Meyer, PhD, Thomas Jefferson University, Sidney Kimmel Comprehensive Can cer Center Meyer: CellCentric: Research Funding. Learn about what the ASH-EHA Translational Research Training…
Studying Anti-MDM2 PROTAC May Yield New Modality in p53-Mutated Cancer
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Breast Cancer Symposium | Jefferson Health
Join Jefferson’s top breast care experts as they share the latest advances in clinical treatments, research and the future of breast cancer.
Cannabis in Cancer: What Oncologists and Patients Should Know
Many people with cancer are interested in using cannabis for symptom management, but few talk to their doctor about it. ASCO guidelines suggest making it…
Coping With Metastatic Breast Cancer as a Young Adult
Diagnosed with stage IV breast cancer at age 25, Lourdes Monje is keeping their cancer in check by participating in a clinical trial.